Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 324

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 324
---
 for us or establishing such capabilities ourselves;

    ●
    the
    costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;

    ●
    the
    magnitude of our general and administrative expenses; and

    ●
    any
    cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.

68

Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and
achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years,
if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical
companies’ stock have been highly volatile as a result of current macroeconomic conditions and market volatility. As a result,
we may face difficulties raising capital through sales of our common stock on acceptable terms, if at all. If we are unsuccessful in
securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely
affect our business prospects, or cease operations. For additional information, see Note 1 to our consolidated financial statements included
elsewhere in this Annual Report and “Risk Factors” in Item 1A. of this Annual Report.

Contractual
Obligations

Operating
lease liabilities represent our commitment for future rent made under a non-cancelable lease for our offices in San Diego, CA. The total
future payments for our operating lease obligation on December 31, 2024 were approximately $0.1 million and are due in the next twelve
months. For additional details regarding our lease, see Note 7 to our consolidated financial statements included in this Annual Report.

We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the SEC
rules.

Critical
Accounting Policies

This
discussion and analysis of our financial condition and results of operations is